Viewing nowSita Tablet 50 mg (Sitagliptin Phosphate Monohydrate)
Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Hanmi Pharmaceutical Co., Ltd.

MFDS item code 201504252 · Approved 2015.06.30 · Insurance code 643507300
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise to help patients with type 2 diabetes manage their blood sugar levels more effectively. It can be used alone or in combination with other diabetes medications. This helps improve blood sugar management and aids in controlling symptoms of diabetes. Therefore, this medication is used for blood sugar control in patients with type 2 diabetes.
This drug is administered at 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This drug may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. (See Precautions for Use, section 5, General Precautions.) Patients with renal impairment Because dose adjustment is required according to renal function, assessment of renal function before treatment with this drug and periodically during treatment is recommended. 1. No dose adjustment is required in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is required in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This drug may be administered regardless of the timing of dialysis.
This medication may cause serious allergic reactions, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur, discontinue use immediately and consult a healthcare professional. During treatment, acute pancreatitis may occur, so if symptoms such as abdominal pain, nausea, or vomiting arise, promptly visit a hospital. Patients with type 1 diabetes or diabetic ketoacidosis should not take this medication. Avoid this medication if you have an allergy to it or its components. Patients with decreased kidney function must adjust the dose of this medication and take it according to a doctor's instructions. When taking this medication with other blood glucose-lowering agents, there may be an increased risk of hypoglycemia, so be alert for symptoms of hypoglycemia and check blood sugar levels frequently if needed. Symptoms such as headaches, upper respiratory infections, nasopharyngitis, indigestion, diarrhea, nausea, increased blood triglycerides, gastritis, weight loss, hypertension, hypernatremia, and erectile dysfunction may occur during treatment; report any severe or persistent symptoms to your doctor. If severe joint pain or blistering skin symptoms occur, discontinue this medication immediately and consult a healthcare professional. Pregnant or nursing women are advised not to take this medication, and the safety and efficacy for children or adolescents under 18 years have not been adequately confirmed. Older adults should undergo kidney function tests before taking this medication, as kidney function may decline, and should regularly monitor kidney function during treatment. In the case of overdose, immediately go to a hospital for appropriate treatment; this medication can be partially removed through hemodialysis, so dialysis treatment may be considered if necessary.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly closed container to prevent air exposure, at room temperature between 1°C and 30°C. Proper storage will help maintain the efficacy of the medication and prevent deterioration.
Yellow, round, biconvex film-coated tablet
30 tablets/box [10 tablets/PTPX3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowSitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Hanmi Pharmaceutical Co., Ltd.

Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Jongkeundang Co., Ltd.

Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Sitagliptin Phosphate Hydrate 32.13mg
Tablet · Prescription medication
Jong Kundang Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Vivozon Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 32.125mg
Tablet · Prescription medication
Sinpoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.